Novocure logo
background

Recurrent GBM Quality of Life

Page title image

In recurrent GBM,

Patients treated with Optune Gio had improved cognitive and emotional functioning1,*

Quality of life: Overall results2

Bar chart comparing baseline to 3-month change in functioning scores for Optune Gio versus chemotherapy, highlighting improvements in cognitive, emotional, and physical functioning.

*Therapy options were the physician’s best choice for chemotherapy. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.2 

  • No clinically meaningful differences were found in global health and social functioning2
  • Data collected by EORTC QLQ-C30 questionnaire2 

Fewer treatment-related adverse events occurred in patients treated with Optune Gio1

Quality of Life: Common Cancer Treatment-Related Adverse Events2

Bar chart of symptom score changes from baseline to 3 months, comparing Optune Gio with chemotherapy, showing improvement in constipation and diarrhea with Optune Gio.

*Therapy options were the physician's best choice for chemotherapy. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.2 

  • Optune Gio monotherapy was associated with more favorable changes in patient-reported symptoms2
  • Data collected by EORTC QLQ-C30 questionnaire2 
Optune Gio user fishing outdoors, smiling and enjoying recreational time, promoting quality of life.

Kim is an Optune Gio user and Patient Ambassador. Patient images reflect the health status of the patient at the time each photo was taken.

Learn about Optune Gio’s safety profile in recurrent GBM

EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; GBM, glioblastoma. 

References: 1. Optune Gio. Instructions For Use. Novocure; 2023. 2. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomized phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.

Indications For Use

Optune Gio® is intended as a treatment for adult patients (22 years of age or older) with histologically confirmed glioblastoma multiforme (GBM).

 

Optune Gio with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

 

For the treatment of recurrent GBM, Optune Gio is indicated following histologically or radiologically confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
 

Important Safety Information

Contraindications

Do not use Optune Gio in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune Gio together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune Gio together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune Gio ineffective.

 

Do not use Optune Gio in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Gio may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

 

Warnings and precautions

Optune Gio can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

 

Do not prescribe Optune Gio for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune Gio in these populations have not been established.

 

The most common (≥10%) adverse events involving Optune Gio in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

 

The most common (≥10%) adverse events seen with Optune Gio monotherapy were medical device site reaction and headache.
The following adverse reactions were considered related to Optune Gio when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall, and skin ulcer.

 

Use of Optune Gio in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune Gio in these patients could lead to tissue damage or lower the chance of Optune Gio being effective.

 

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune Gio treatment.

Please click here to see the Optune Gio® Instructions For Use for complete information regarding the device’s indications, contraindications, warnings, and precautions.

Novocure Websites

This website is intended for people seeking information on Optune Gio.

 

On this site, videos and images identified as Optune Gio users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals.

 

Patient images reflect the health status of the patients at the time each photo or video was taken.

 

External links

Optunegio.com
Optunelua.com
Novocuretrials.com

Quick links

What Is Optune Gio?
Mechanism of Action
International
Frequently Asked Questions
Contact Us

Legal links

Terms of Use
Privacy Notice
Novocure logo

©2025 Novocure GmbH. All Rights Reserved.  

MyLink, MyNovocure, Novocure, and Optune Gio are registered trademarks of Novocure GmbH. 

All other trademarks, registered or unregistered, are the property of their respective owners.

US-OPG-00197v1.0 February 2025 

 

US-OPG-00197 v1.0 February 2025